Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes

Rong Wang; Cary P. Gross; Ronald J. Maggiore; Stephanie Halene; Pamela R. Soulos; Azra Raza; Naomi Galili; Xiaomei Ma

doi:10.1016/j.leukres.2010.10.007

Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes

Rong Wang, Cary P. Gross, Ronald J. Maggiore, Stephanie Halene, Pamela R. Soulos, Azra Raza, Naomi Galili, Xiaomei Ma

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Little is known about how hypomethylating agents (HMAs) have been adopted into the treatment of myelodysplastic syndromes (MDS). We conducted a population-based study to assess the use of HMAs among 4416 MDS patients (age ≥66 years) who were diagnosed during 2001-2005 and followed up through the end of 2007. Multivariate logistic regression models were utilized to evaluate the role of various patient characteristics. 475 (10.8%) patients had received HMAs by 2007, with the proportion increasing over time. Patients who were white (odds ratio (OR)=0.66, 95% confidence interval (CI): 0.46-0.95), male (OR=1.47, 95% CI: 1.19-1.82), young (P_trend<0.01), more recently diagnosed (OR=1.90, 95% CI: 1.54-2.34), had fewer comorbidities (P_trend<0.01), or had a history of other cancer (OR=1.28, 95% CI: 1.00-1.63) were more likely to receive HMAs. Compared with patients with refractory anemia, those diagnosed with refractory anemia with excess blasts or refractory cytopenia with multilineage dysplasia had a higher chance to be treated with HMAs (OR=3.52 and 2.32, respectively). Relatively few MDS patients were treated with HMAs during the introduction period of these agents, and multiple patient characteristics such as sex, comorbidities, and MDS subtype influence the likelihood a patient receives HMAs.

Original language	English (US)
Pages (from-to)	904-908
Number of pages	5
Journal	Leukemia Research
Volume	35
Issue number	7
DOIs	https://doi.org/10.1016/j.leukres.2010.10.007
State	Published - Jul 2011
Externally published	Yes

Keywords

Chemotherapy
Hematology-medical
Myelodysplastic syndromes
New agents

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2010.10.007

Cite this

@article{e218c3dbb74a434dbfb4b5793630d311,

title = "Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes",

abstract = "Little is known about how hypomethylating agents (HMAs) have been adopted into the treatment of myelodysplastic syndromes (MDS). We conducted a population-based study to assess the use of HMAs among 4416 MDS patients (age ≥66 years) who were diagnosed during 2001-2005 and followed up through the end of 2007. Multivariate logistic regression models were utilized to evaluate the role of various patient characteristics. 475 (10.8%) patients had received HMAs by 2007, with the proportion increasing over time. Patients who were white (odds ratio (OR)=0.66, 95% confidence interval (CI): 0.46-0.95), male (OR=1.47, 95% CI: 1.19-1.82), young (Ptrend<0.01), more recently diagnosed (OR=1.90, 95% CI: 1.54-2.34), had fewer comorbidities (Ptrend<0.01), or had a history of other cancer (OR=1.28, 95% CI: 1.00-1.63) were more likely to receive HMAs. Compared with patients with refractory anemia, those diagnosed with refractory anemia with excess blasts or refractory cytopenia with multilineage dysplasia had a higher chance to be treated with HMAs (OR=3.52 and 2.32, respectively). Relatively few MDS patients were treated with HMAs during the introduction period of these agents, and multiple patient characteristics such as sex, comorbidities, and MDS subtype influence the likelihood a patient receives HMAs.",

keywords = "Chemotherapy, Hematology-medical, Myelodysplastic syndromes, New agents",

author = "Rong Wang and Gross, {Cary P.} and Maggiore, {Ronald J.} and Stephanie Halene and Soulos, {Pamela R.} and Azra Raza and Naomi Galili and Xiaomei Ma",

note = "Funding Information: This work was supported by a research grant from the National Cancer Institute ( R21 CA131927 ). This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. ",

year = "2011",

month = jul,

doi = "10.1016/j.leukres.2010.10.007",

language = "English (US)",

volume = "35",

pages = "904--908",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "7",

}

TY - JOUR

T1 - Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes

AU - Wang, Rong

AU - Gross, Cary P.

AU - Maggiore, Ronald J.

AU - Halene, Stephanie

AU - Soulos, Pamela R.

AU - Raza, Azra

AU - Galili, Naomi

AU - Ma, Xiaomei

N1 - Funding Information: This work was supported by a research grant from the National Cancer Institute ( R21 CA131927 ). This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database.

PY - 2011/7

Y1 - 2011/7

N2 - Little is known about how hypomethylating agents (HMAs) have been adopted into the treatment of myelodysplastic syndromes (MDS). We conducted a population-based study to assess the use of HMAs among 4416 MDS patients (age ≥66 years) who were diagnosed during 2001-2005 and followed up through the end of 2007. Multivariate logistic regression models were utilized to evaluate the role of various patient characteristics. 475 (10.8%) patients had received HMAs by 2007, with the proportion increasing over time. Patients who were white (odds ratio (OR)=0.66, 95% confidence interval (CI): 0.46-0.95), male (OR=1.47, 95% CI: 1.19-1.82), young (Ptrend<0.01), more recently diagnosed (OR=1.90, 95% CI: 1.54-2.34), had fewer comorbidities (Ptrend<0.01), or had a history of other cancer (OR=1.28, 95% CI: 1.00-1.63) were more likely to receive HMAs. Compared with patients with refractory anemia, those diagnosed with refractory anemia with excess blasts or refractory cytopenia with multilineage dysplasia had a higher chance to be treated with HMAs (OR=3.52 and 2.32, respectively). Relatively few MDS patients were treated with HMAs during the introduction period of these agents, and multiple patient characteristics such as sex, comorbidities, and MDS subtype influence the likelihood a patient receives HMAs.

AB - Little is known about how hypomethylating agents (HMAs) have been adopted into the treatment of myelodysplastic syndromes (MDS). We conducted a population-based study to assess the use of HMAs among 4416 MDS patients (age ≥66 years) who were diagnosed during 2001-2005 and followed up through the end of 2007. Multivariate logistic regression models were utilized to evaluate the role of various patient characteristics. 475 (10.8%) patients had received HMAs by 2007, with the proportion increasing over time. Patients who were white (odds ratio (OR)=0.66, 95% confidence interval (CI): 0.46-0.95), male (OR=1.47, 95% CI: 1.19-1.82), young (Ptrend<0.01), more recently diagnosed (OR=1.90, 95% CI: 1.54-2.34), had fewer comorbidities (Ptrend<0.01), or had a history of other cancer (OR=1.28, 95% CI: 1.00-1.63) were more likely to receive HMAs. Compared with patients with refractory anemia, those diagnosed with refractory anemia with excess blasts or refractory cytopenia with multilineage dysplasia had a higher chance to be treated with HMAs (OR=3.52 and 2.32, respectively). Relatively few MDS patients were treated with HMAs during the introduction period of these agents, and multiple patient characteristics such as sex, comorbidities, and MDS subtype influence the likelihood a patient receives HMAs.

KW - Chemotherapy

KW - Hematology-medical

KW - Myelodysplastic syndromes

KW - New agents

UR - http://www.scopus.com/inward/record.url?scp=79958721648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958721648&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2010.10.007

DO - 10.1016/j.leukres.2010.10.007

M3 - Article

C2 - 21067809

AN - SCOPUS:79958721648

SN - 0145-2126

VL - 35

SP - 904

EP - 908

JO - Leukemia Research

JF - Leukemia Research

IS - 7

ER -

Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this